Enhanced pharmacist care for patients with dyslipidemia improves low-density lipoprotein cholesterol levels, according to a study published in the March issue of Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.
Enhanced pharmacist care for patients with dyslipidemia improves low-density lipoprotein (LDL) cholesterol levels, according to a study published in the March issue of Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.
The study, led by Theresa L. Charrois, BScPharm, MSc, included the systematic review of 21 randomized, controlled trials.
The primary outcome measure assessed was the difference, at the end of the follow-up, in LDL cholesterol levels between the groups of dyslipidemia patients who had pharmacist intervention and those who had standard care.
The researchers also looked at the difference between the groups in total cholesterol, high-density lipoprotein cholesterol, and triglyceride levels.
At the end of follow-up, the mean LDL level was 10.7 mg/dL lower in the enhanced pharmacy care groups compared to the standard care groups. In addition, the mean cholesterol level was significantly lower in the enhanced pharmacy care groups compared with the standard care groups.
Patients who received enhanced pharmacist care were also more likely than those receiving standard care to achieve target lipid parameters and to have a lipid panel ordered or recommended by a pharmacist during the study.
“Patients in the pharmacist intervention groups were almost twice as likely as patients in the standard care groups to have a change in lipid-lowering therapies. These results point to the benefit that pharmacist care can provide across the spectrum of dyslipidemia management,” the researchers stated.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.